Thanks for reading! We look for high quality stocks trading at attractive valuations in our award winning Marketplace service entitled Cash Flow Compounders: The Best Stocks in the World. Our focus is high return on equity, high free cash flow stocks with a proven track record in compounding earnings at higher than market rates. There we provide in depth research, with 2-4 new, high quality ideas per month. Our portfolios have earned returns well above benchmark levels. Sign up for a free 2 week trial to ge ...

Core Viewpoint - The focus is on investing in companies with strong qualitative attributes, purchasing them at attractive prices based on fundamentals, and holding them long-term [1]. Group 1: Investment Strategy - The investment strategy involves managing a concentrated portfolio aimed at avoiding underperforming stocks while maximizing exposure to high-potential winners [1]. - Companies may be rated as 'Hold' if their growth opportunities do not meet the analyst's threshold or if their downside risks are deemed too high [1]. Group 2: Analyst Background - The analyst holds an MBA and an L.L.B in law, currently working as a financial analyst at a large pension fund [1].

Group 1 - The article discusses the author's journey into investing, starting in high school in 2011, focusing on REITs, preferred stocks, and high-yield bonds, indicating a long-standing interest in markets and the economy [1] - The author has recently adopted a strategy that combines long stock positions with covered calls and cash secured puts, emphasizing a fundamental long-term investment approach [1] - The author primarily covers REITs and financials on Seeking Alpha, with occasional articles on ETFs and other stocks influenced by macro trade ideas [1]

Universal Health Services, Inc. (UHS) reported fourth-quarter 2024 adjusted earnings per share (EPS) of $4.92, which beat the Zacks Consensus Estimate by 17.4%. The bottom line climbed 17.4% year over year.See the Zacks Earnings Calendar to stay ahead of market-making news.Net revenues advanced 11.1% year over year to nearly $4.1 billion. The top line beat the consensus mark by 3%.The strong quarterly results of UHS were aided by continued growth in admissions at its acute care facilities and behavioral, re ...

Core Insights - Universal Health Services, Inc. (UHS) is scheduled to report its fourth-quarter 2024 results on February 26, 2025, with earnings estimated at $4.19 per share and revenues at $3.99 billion [1][2] Earnings Estimates - The earnings estimate for the fourth quarter has increased by $0.01 over the past week, indicating a year-over-year increase of 33.9%, while the revenue estimate suggests a growth of 7.9% year-over-year [2] - UHS has beaten the consensus earnings estimate in three of the last four quarters, with an average surprise of 12.1% [3] Earnings Prediction Model - The current model does not predict a definitive earnings beat for UHS, as it has an Earnings ESP of +2.03% but a Zacks Rank of 4 (Sell) [4] Revenue Drivers - The revenue growth is expected to be driven by strong performance in the Acute Care Hospital Services and Behavioral Health Care Services segments [6] - The Acute Care Hospital Services segment is projected to generate net revenues of $2.26 billion, reflecting an 8.2% year-over-year growth, with adjusted admissions expected to grow by 2.6% [7] - The Behavioral Health Care Services segment is estimated to achieve net revenues of $1.74 billion, indicating a 7.6% increase from the prior year, supported by a 5% increase in adjusted patient days [9] Cost Pressures - Despite the anticipated revenue growth, UHS's margins may face pressure from rising expenses, particularly in salaries, wages, and benefits, which are expected to increase by 4.3% year-over-year, along with a 1.2% rise in supply costs [10]

Core Insights - Universal Display Corporation (OLED) reported strong fourth-quarter 2024 results, with adjusted earnings and revenues exceeding Zacks Consensus Estimates, driven by robust material sales growth [1][4] - The company anticipates continued growth in the consumer electronics market, with strategic measures in place to enhance its operational and strategic infrastructure [2][10] Financial Performance - Net income for Q4 2024 was $46 million or $0.96 per share, down from $62 million or $1.29 per share in the previous year, impacted by higher operating expenses and restructuring charges [3] - Adjusted earnings for Q4 2024 were $1.22 per share, surpassing the Zacks Consensus Estimate of $1.07 [3] - Total revenues for Q4 2024 reached $162.3 million, an increase from $158.3 million in the prior year, exceeding the consensus estimate of $149 million [4] - For the full year 2024, net income was $222.1 million or $4.65 per share, compared to $203 million or $4.24 per share in 2023 [3] - Full-year revenues for 2024 were $647.7 million, up from $576.4 million in 2023 [4] Revenue Breakdown - Material sales contributed $93.3 million to revenues in Q4 2024, up from $82.2 million in the prior-year quarter, exceeding estimates [5] - Revenues from green emitter sales increased to $67 million from $63 million, while red emitter sales rose to $25 million from $18 million [5] - Royalty and license fees were $64 million, down from $72.9 million in the previous year, but still above estimates [5] - Contract research services generated $4.6 million, an increase from $3.2 million, but missed estimates [6] Profitability Metrics - Quarterly gross profit rose to $124.9 million from $122.3 million, maintaining a gross margin of 77% [7] - Operating income was $52.5 million with a margin of 32%, down from $64.7 million and 41% in the prior year [7] Cash Flow and Liquidity - In 2024, cash generated from operating activities was $253.7 million, compared to $154.77 million in the previous year [8] - As of December 31, 2024, cash and cash equivalents stood at $99 million, up from $92 million in 2023 [8] Future Guidance - For 2025, the company projects revenues between $640 million and $700 million, with a gross margin forecast of 76-77% and an operating margin of 35-40% [9]

Core Insights - Demand for HVACR technicians is projected to grow by 9 percent from 2023 to 2033, significantly outpacing the average growth rate for all occupations, indicating a strong need for skilled professionals in this field [2][4]. Company Overview - Universal Technical Institute (UTI) is expanding its offerings by launching a new HVACR program at its Orlando campus in March, adding to its existing four programs [1][4]. - The HVACR program will cover essential topics such as air handling, AC and DC circuits, sheet metal ductwork, and troubleshooting mechanical and electronic controls [3]. Industry Context - The expansion of the HVACR program aligns with UTI's corporate strategy focused on growth, diversification, and optimization, which includes launching eight full-length programs across existing campuses and establishing a new campus in Atlanta [4].

Company Overview - Cidara Therapeutics is a small biotech company focused on developing drug-Fc conjugates (DFCs) for influenza prevention [1] - The company utilizes a proprietary platform named Cloudbreak to develop its main product, CD388 [1] Product Development - CD388 is positioned as the primary product in Cidara's pipeline, indicating a strategic focus on innovative therapeutic solutions for influenza [1]

Unauthorized Payments and Investigation - Universal Corporation reported approximately $16.7 million in unauthorized payments identified during fiscal years 2016 through 2025, with about $7 million occurring in fiscal years 2022 through 2025[8]. - The company is currently unable to predict the outcome or timeframe for the completion of the ongoing internal investigation related to the embezzlement case[9]. - Universal Corporation expects to report one or more material weaknesses in its internal control over financial reporting following the investigation[11]. - The ongoing investigation may not have a material impact on the company's financial results for fiscal year 2025[10]. - Universal Corporation is pursuing sources of recovery, including insurance, related to the unauthorized payments[10]. - The company has not finalized its financial statements for the second and third quarters of fiscal year 2025 due to the investigation[11]. - The company is evaluating the design and effectiveness of its internal control over financial reporting as part of the investigation[11]. - Universal Corporation's management is working diligently to complete the investigation and review the circumstances surrounding the embezzlement[9]. Financial Reporting and Statements - The company has entered into a Consent with lenders to extend the delivery of its quarterly financial statements until June 16, 2025[7]. - The preliminary unaudited financial results for the quarter ended December 31, 2024, are based on currently available information and may differ from actual results[4].

Core Viewpoint - Universal Health Services (NYSE: UHS) is identified as a stable mid-cap healthcare company with a strong history of value creation for shareholders, initially recommended as a buy in July 2024 [1]. Group 1: Company Overview - Universal Health Services has been recognized for its consistent performance and value generation in the healthcare sector [1]. - The company is analyzed using Cash Flow Returns On Investment based DCF valuation tools, indicating a systematic approach to valuation [1]. Group 2: Research and Analysis - The analysis is supported by ROCGA Research, which has over 20 years of experience in investment analysis, focusing on identifying undervalued and quality companies [1]. - ROCGA Research provides an online platform that offers an objective framework for company valuation [1].